TLSA - Tiziana Life Sciences Ltd Stock Price and Quote

TLSA [NASD]

Healthcare | Biotechnology | United Kingdom

Index	-	P/E	-	EPS (ttm)	-0.17	Insider Own	43.01%	Shs Outstand	97.93M	Perf Week	-1.27%
Market Cap	64.90M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	58.29M	Perf Month	0.34%
Income	-10.50M	PEG	-	EPS next Q	-	Inst Own	5.20%	Short Float / Ratio	0.11% / 1.26	Perf Quarter	-7.41%
Sales	-	P/S	-	EPS this Y	0.70%	Inst Trans	-0.07%	Short Interest	0.07M	Perf Half Y	-18.44%
Book/sh	0.30	P/B	2.00	EPS next Y	-	ROA	-	Target Price	4.00	Perf Year	-22.44%
Cash/sh	0.24	P/C	2.45	EPS next 5Y	-	ROE	-	52W Range	0.53 - 1.38	Perf YTD	3.59%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-55.07%	Beta	0.63
Dividend %	-	Quick Ratio	6.10	Sales past 5Y	-	Gross Margin	-	52W Low	17.27%	ATR	0.05
Employees	14	Current Ratio	6.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	47.88	Volatility	7.32% 9.80%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-75.90%	Profit Margin	-	Rel Volume	2.07	Prev Close	0.60
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	51.99K	Price	0.62
Recom	2.00	SMA20	-2.25%	SMA50	0.22%	SMA200	-14.97%	Volume	23,989	Change	3.33%

Dec-22-20

Initiated

B. Riley Securities

Buy

Dec-17-18

Initiated

Laidlaw

Buy

Jan-08-23 08:53AM	Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Jan-04-23 07:00AM	Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer GlobeNewswire +8.09%
Jan-03-23 11:11AM	Tiziana Life Sciences Posts Additional Clinical Improvements In Second Patient with Multiple Sclerosis Benzinga
07:00AM	Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab GlobeNewswire
Dec-29-22 05:00PM	Tiziana Life Sciences Ltd (Tiziana or the Company) - Updated Interim Results for the Six Months Ended 30 June 2022 GlobeNewswire
05:00PM	Loading…
Dec-27-22 05:00PM	Tiziana Life Sciences Ltd (Tiziana or the Company) - Interim Results for the Six Months Ended 30 June 2022 GlobeNewswire -6.67%
Dec-16-22 07:00AM	Tiziana to Participate in January Investor Meetings GlobeNewswire
Dec-15-22 07:00AM	Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study GlobeNewswire
Dec-14-22 06:00AM	Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements GlobeNewswire
Dec-06-22 07:00AM	Tiziana Life Sciences Announces Date of Annual General Meeting 2022 GlobeNewswire
Dec-05-22 03:00AM	TLSA: Novembers Investor Day Zacks Small Cap Research
Nov-23-22 10:59AM	Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects GlobeNewswire
Nov-10-22 07:00AM	Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS) GlobeNewswire +11.29%
Nov-04-22 07:00AM	Tiziana Life Sciences to Host Investor Call GlobeNewswire
Nov-03-22 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman GlobeNewswire
07:00AM	Loading…
Nov-02-22 07:00AM	Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients GlobeNewswire
Oct-26-22 07:00AM	Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients GlobeNewswire
Oct-19-22 07:00AM	Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference GlobeNewswire
Oct-13-22 05:46AM	TLSA: New Management Takes the Reins Zacks Small Cap Research
Oct-12-22 07:00AM	Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients GlobeNewswire
Sep-29-22 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer GlobeNewswire
Sep-28-22 07:00AM	Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the Preserving the Brain Scientific Conference and Exhibit at the Fondazione Prada in Milan GlobeNewswire
Sep-23-22 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer GlobeNewswire
Sep-21-22 07:30AM	Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman GlobeNewswire +9.87%
Sep-20-22 06:34AM	Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab GlobeNewswire
Sep-16-22 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman GlobeNewswire -33.73%
Sep-15-22 07:00AM	Tiziana Life Sciences Announces Grant received by the Brigham and Womens Hospital to Explore the Use of Intranasal anti-CD3 mAb in Amyotrophic Lateral Sclerosis GlobeNewswire
Sep-09-22 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer GlobeNewswire
Aug-25-22 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman GlobeNewswire +5.96%
Aug-17-22 07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman GlobeNewswire
04:24PM	Loading…
Aug-16-22 04:24PM	Investing in Electric Vehicles and Green Transportation Investopedia
Aug-01-22 09:05AM	Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans? Simply Wall St.
08:00AM	Tiziana Life Sciences Announces Presentation at Alzheimers Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimers Disease GlobeNewswire
Jul-18-22 06:00AM	Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer GlobeNewswire
Jul-15-22 04:15PM	Tiziana Life Sciences Announces Resignation of CEO GlobeNewswire +6.59%
Jun-17-22 04:30PM	Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice GlobeNewswire
Jun-10-22 08:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman GlobeNewswire -6.04%
Jun-09-22 12:53PM	Tiziana Life Sciences PLC (TLSA: NASDAQ) Releases Research Report: Clinical Improvements for 2nd SPMS Patient GlobeNewswire
12:25PM	Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient GlobeNewswire
12:04PM	Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient GlobeNewswire
07:00AM	Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman GlobeNewswire
05:26AM	TLSA: Clinical Improvements for 2nd SPMS Patient Zacks Small Cap Research
Jun-08-22 12:01PM	Tiziana Life Sciences Shares Jump After Multiple Sclerosis Data From Second Patient Benzinga +8.33%
07:00AM	Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab GlobeNewswire
Jun-06-22 07:00AM	Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical Programs GlobeNewswire
Jun-01-22 07:00AM	Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting GlobeNewswire +8.32%
May-24-22 05:56PM	Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance GlobeNewswire
Apr-26-22 11:43AM	Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference GlobeNewswire +7.47%
Apr-05-22 07:00AM	FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab GlobeNewswire
Mar-25-22 07:00AM	Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohns Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody GlobeNewswire
Mar-15-22 02:15PM	Tiziana Announces Availability of March 14 KOL Event Replay GlobeNewswire -7.18%
06:02AM	TLSA: KOL Discussion and SPMS 6-Month Results Zacks Small Cap Research
Mar-11-22 07:17AM	Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis GlobeNewswire +8.82%
Mar-10-22 07:00AM	Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody GlobeNewswire +30.42%
Mar-04-22 07:00AM	AccuStem Sciences, Inc. Appoints New Executive Leadership Team GlobeNewswire +5.57%
Mar-01-22 09:05AM	StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort GlobeNewswire +18.60%
Feb-10-22 07:00AM	Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference GlobeNewswire +5.69%
Feb-04-22 07:00AM	Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohns Disease GlobeNewswire
Jan-26-22 07:00AM	Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Oncology Conference GlobeNewswire -7.12%
Jan-24-22 11:12AM	Tiziana Life Sciences Ltd. To Implement Stock Repurchase Program for up to $5 Million GlobeNewswire
Jan-13-22 07:00AM	Tiziana Life Sciences Announces Death of Director GlobeNewswire -6.77%
Jan-11-22 04:12AM	TLSA: SPMS Update; Second Patient Gains Access Zacks Small Cap Research -5.57%
Jan-10-22 07:00AM	Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis GlobeNewswire -5.86%
Jan-06-22 04:15PM	Tiziana Life Sciences to Participate in 2022 Biotech Showcase Virtual Investor Conference GlobeNewswire
Oct-21-21 02:00AM	Share Capital Consolidation and Commencement of trading in the New Tiziana Shares on NASDAQ GlobeNewswire -9.64%
Oct-20-21 09:40AM	Tiziana Life Sciences - Scheme Effective Date GlobeNewswire +12.93%
02:00AM	Tiziana Life Sciences plc: PDMR Dealing GlobeNewswire
Oct-19-21 09:26AM	Tiziana Life Sciences plc: Court Sanctions the Scheme of Arrangement and approves Reduction of Capital GlobeNewswire
Oct-07-21 06:10AM	TLSA: 1H:21 Financial Update Zacks Small Cap Research
Sep-28-21 04:19AM	Tiziana Life Sciences plc: PDMR Dealing GlobeNewswire -6.37%
Sep-27-21 12:39PM	Tiziana Life Sciences Plc - Results of Court Meeting and General Meeting GlobeNewswire
Sep-24-21 12:51PM	Tiziana Life Sciences plc - Interim Results for the Six Months Ended 30 June 2021 GlobeNewswire -5.03%
Sep-20-21 07:45AM	TLSA: Partnership with Precision Zacks Small Cap Research
Sep-07-21 02:00AM	Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment GlobeNewswire
Sep-03-21 10:27AM	Precision (DTIL) Inks Deal With Tiziana for Cancer Candidate Zacks
02:00AM	Tiziana Life Sciences plc Posting of Scheme Document and Notice of Meetings GlobeNewswire
Sep-02-21 09:42AM	Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications Benzinga +21.21%
06:02AM	TLSA: Foralumab Now in CAR T Zacks Small Cap Research
02:00AM	Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment GlobeNewswire
02:00AM	Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment Business Wire
Aug-20-21 02:00AM	Tiziana Life Sciences plc files scheme of arrangement to effect a corporate reorganisation and, if approved, the delisting of its ordinary shares in London and the direct listing of common shares in the new parent company of the Tiziana group on NASDAQ GlobeNewswire
Aug-17-21 02:00AM	Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in Brazil GlobeNewswire
Aug-16-21 04:36PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Tesla, Inc. (NASDAQ:TSLA) Investigation ACCESSWIRE
01:14PM	Tiziana Life Sciences plc Invites You to Join Us at the Q3 Virtual Investor Summit Newsfile
Aug-04-21 01:56AM	Here's Why We're Not Too Worried About Tiziana Life Sciences' (LON:TILS) Cash Burn Situation Simply Wall St.
Jul-08-21 07:59AM	Tiziana Life Sciences plc - ADS Ex-Dividend Date Scheduled for July 09, 2021 GlobeNewswire
Jul-02-21 07:58AM	Tiziana Life Sciences plc - Distribution Dates for shares and ADRs in Accustem Sciences Limited GlobeNewswire
Jul-01-21 05:40AM	TLSA: Intranasal Foralumab in COVID-19 Zacks Small Cap Research
Jun-30-21 06:47AM	Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.50pm ET today GlobeNewswire
Jun-25-21 06:15AM	Tiziana Life Sciences plc (the "Company") Result of Annual General Meeting GlobeNewswire
Jun-23-21 02:00AM	Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody GlobeNewswire
Jun-21-21 02:00AM	Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs GlobeNewswire
Jun-17-21 02:00AM	Tiziana Responds to UK Call for Development of Innovative Take Home Treatments for COVID-19 Disease GlobeNewswire +6.30%
Jun-02-21 02:00AM	Tiziana Life Sciences plc ("Tiziana" or the Company) Posting of Notice of Annual General Meeting GlobeNewswire -7.53%
May-27-21 07:14AM	TLSA: Nasally-administered Foralumab Trial in SPMS Patient Zacks Small Cap Research -5.60%
May-26-21 06:37AM	Tiziana Life's Foralumab Induces Immunomodulation, Anti-Inflammatory Effects In Early-Stage Study Benzinga
02:00AM	Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers GlobeNewswire
May-25-21 06:16AM	Tiziana Life Starts Testing Nasally Administered Foralumab in Multiple Sclerosis Patients Benzinga
02:00AM	Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program GlobeNewswire
May-07-21 02:00AM	Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report GlobeNewswire

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience